Last reviewed · How we verify

NCT07335185: GRASSROOT Reg

Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes

Not yet recruiting NA Last updated 13 January 2026
What this trial tests

NA trial testing Supernova revascularization device in Stroke in 3,000 participants. Not yet recruiting.

Timeline
1 January 2026
Primary endpoint
31 October 2030
31 December 2030

Quick facts

Lead sponsorGravity Medical Technology, INC
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment3,000
Start date1 January 2026
Primary completion31 October 2030
Estimated completion31 December 2030

Drugs / interventions tested

Conditions studied

Sponsor

Gravity Medical Technology, INC

Who can join

Eligibility, any sex, with Stroke or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Supernova revascularization device

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Gravity Medical Technology, INC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07335185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing